TY - JOUR
T1 - Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response
AU - Fiori, Laura M.
AU - Lopez, Juan Pablo
AU - Richard-Devantoy, Stéphane
AU - Berlim, Marcelo
AU - Chachamovich, Eduardo
AU - Jollant, Fabrice
AU - Foster, Jane
AU - Rotzinger, Susan
AU - Kennedy, Sidney H.
AU - Turecki, Gustavo
N1 - Funding Information:
This research was funded by the Canadian Institutes of Health Research and with the support of the Canadian Biomarker Integration Network in Depression (CAN-BIND), an Integrated Discovery Program, with funding from the Ontario Brain Institute, an independent nonprofit corporation, funded partially by the Ontario government. Additional funding for CAN-BIND was provided by the CIHR, Brain Canada, Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier.
Funding Information:
S.H.K. has received research funding or honoraria from the following sources: Allergan, AstraZeneca, BMS, Brain Canada, Canadian Institutes for Health Research (CIHR), Eli Lilly, Janssen, Lundbeck, Lundbeck Institute, OMHF, Ontario Brain Institute, Ontario Research Fund (ORF), Pfizer, Servier, St. Jude Medical, Sunovion and Xian-Janssen. G.T. holds a Canada Research Chair (Tier 1), Fonds de Recherche du Québec - Santé Chercheur National salary award, and a NARSAD Distinguished Investigator Award. G.T. is supported by grants from the CIHR (FDN148374, MOP93775, MOP11260, MOP119429, and MOP119430), from the US National Institutes of Health (1R01DA033684), by the FRQS through the Quebec Network on Suicide, Mood Disorders and Related Disorders, and through an investigator-initiated research grant from Pfizer.
Publisher Copyright:
© The Author 2017.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background: Major depressive disorder is a debilitating illness, which is most commonly treated with antidepressant drugs. As the majority of patients do not respond on their first trial, there is great interest in identifying biological factors that indicate the most appropriate treatment for each patient. Studies suggest that microRNA represent excellent biomarkers to predict antidepressant response. Methods: We investigated the expression of miR-1202, miR-135a, and miR-16 in peripheral blood from 2 cohorts of depressed patients who received 8 weeks of antidepressant therapy. Expression was quantified at baseline and after treatment, and its relationship to treatment response and depressive symptoms was assessed. Results: In both cohorts, responders displayed lower baseline miR-1202 levels compared with nonresponders, which increased following treatment. Conclusions: Ultimately, our results support the involvement of microRNA in antidepressant response and suggest that quantification of their levels in peripheral samples represents a valid approach to informing treatment decisions.
AB - Background: Major depressive disorder is a debilitating illness, which is most commonly treated with antidepressant drugs. As the majority of patients do not respond on their first trial, there is great interest in identifying biological factors that indicate the most appropriate treatment for each patient. Studies suggest that microRNA represent excellent biomarkers to predict antidepressant response. Methods: We investigated the expression of miR-1202, miR-135a, and miR-16 in peripheral blood from 2 cohorts of depressed patients who received 8 weeks of antidepressant therapy. Expression was quantified at baseline and after treatment, and its relationship to treatment response and depressive symptoms was assessed. Results: In both cohorts, responders displayed lower baseline miR-1202 levels compared with nonresponders, which increased following treatment. Conclusions: Ultimately, our results support the involvement of microRNA in antidepressant response and suggest that quantification of their levels in peripheral samples represents a valid approach to informing treatment decisions.
KW - Antidepressant response
KW - Major depressive disorder
KW - Microrna
UR - http://www.scopus.com/inward/record.url?scp=85036669563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85036669563&partnerID=8YFLogxK
U2 - 10.1093/ijnp/pyx034
DO - 10.1093/ijnp/pyx034
M3 - Article
C2 - 28520926
AN - SCOPUS:85036669563
SN - 1461-1457
VL - 20
SP - 619
EP - 623
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
IS - 8
ER -